Treatment of blast cell crisis of chronic myeloid leukemia with ICRF-159 (razoxane).
Eleven patients with myeloid blast cell crisis and two patients with lymphoid blast cell crisis of chronic myeloid leukemia were treated with ICRF-159. Two of the patients with myeloid blast cell crisis achieved partial bone marrow remission and survived for 8+ and 18 months. One of the patients with lymphoid blast cell crisis reverted to the chronic phase of chronic myeloid leukemia after therapy with ICRF-159 in combination with prednisolone. The only significant toxic effect was myelosuppression.
D000293:Adolescent; D000328:Adult; D001853:Bone Marrow / Q000187:drug effects; D004359:Drug Therapy, Combination; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011239:Prednisolone / Q000008:administration & dosage; D011929:Razoxane / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D013997:Time Factors
D010879:Piperazines; D011929:Razoxane; D011239:Prednisolone